120 related articles for article (PubMed ID: 31400758)
1. FBXW10 promotes hepatocarcinogenesis in male patients and mice.
Luo YD; Zhang J; Fang L; Zhu YY; You YM; Zhang CC; Zheng P; Zhang LD; Yin LY; Xia F; Bie P; Xie CM
Carcinogenesis; 2020 Jul; 41(5):689-698. PubMed ID: 31400758
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma.
Sun XF; Sun JP; Hou HT; Li K; Liu X; Ge QX
Tumour Biol; 2016 Nov; 37(11):15325-15332. PubMed ID: 27704356
[TBL] [Abstract][Full Text] [Related]
3. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
[TBL] [Abstract][Full Text] [Related]
4. Zinc finger protein ZBTB20 is an independent prognostic marker and promotes tumor growth of human hepatocellular carcinoma by repressing FoxO1.
Kan H; Huang Y; Li X; Liu D; Chen J; Shu M
Oncotarget; 2016 Mar; 7(12):14336-49. PubMed ID: 26893361
[TBL] [Abstract][Full Text] [Related]
5. FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males.
Liu ZY; Lin XT; Zhang YJ; Gu YP; Yu HQ; Fang L; Li CM; Wu D; Zhang LD; Xie CM
Cancer Lett; 2023 Jul; 566():216257. PubMed ID: 37277019
[TBL] [Abstract][Full Text] [Related]
6. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA LINC00324 exerts protumorigenic effects on liver cancer stem cells by upregulating fas ligand via PU box binding protein.
Gao J; Dai C; Yu X; Yin XB; Zhou F
FASEB J; 2020 Apr; 34(4):5800-5817. PubMed ID: 32128906
[TBL] [Abstract][Full Text] [Related]
8. Transmembrane protein 106C promotes the development of hepatocellular carcinoma.
Luo X; Han G; Lu R; Guan S; Wang Y; Ju L; Chen L; Shao J; Bian Z
J Cell Biochem; 2020 Nov; 121(11):4484-4495. PubMed ID: 32037603
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
[TBL] [Abstract][Full Text] [Related]
11. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
Lei X; Li YF; Chen GD; Ou DP; Qiu XX; Zuo CH; Yang LY
Oncotarget; 2015 Dec; 6(38):40622-41. PubMed ID: 26536663
[TBL] [Abstract][Full Text] [Related]
12. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
13. Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma.
Huang T; Guo YZ; Yue X; Zhang GP; Zhang Y; Kuang M; Peng BG; Li SQ
Carcinogenesis; 2020 Jul; 41(5):571-581. PubMed ID: 32649753
[TBL] [Abstract][Full Text] [Related]
14. Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma.
Huang T; Guo YZ; Yue X; Zhang GP; Zhang Y; Kuang M; Peng BG; Li SQ
Carcinogenesis; 2020 Jul; 41(5):571-581. PubMed ID: 32648918
[TBL] [Abstract][Full Text] [Related]
15. Methylation-regulated miR-124-1 suppresses tumorigenesis in hepatocellular carcinoma by targeting CASC3.
Xu L; Dai W; Li J; He L; Wang F; Xia Y; Chen K; Li S; Liu T; Lu J; Zhou Y; Wang Y; Guo C
Oncotarget; 2016 May; 7(18):26027-41. PubMed ID: 27029030
[TBL] [Abstract][Full Text] [Related]
16. HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma.
Zhou ZQ; Zhao JJ; Chen CL; Liu Y; Zeng JX; Wu ZR; Tang Y; Zhu Q; Weng DS; Xia JC
Mol Carcinog; 2019 Jan; 58(1):76-87. PubMed ID: 30182378
[TBL] [Abstract][Full Text] [Related]
17. NKD1 correlates with a poor prognosis and inhibits cell proliferation by inducing p53 expression in hepatocellular carcinoma.
Zhang S; Li J; Wang X
Tumour Biol; 2016 Oct; 37(10):14059-14067. PubMed ID: 27507614
[TBL] [Abstract][Full Text] [Related]
18. APC
Shi M; Dai WQ; Jia RR; Zhang QH; Wei J; Wang YG; Xiang SH; Liu B; Xu L
Cancer Lett; 2021 Jan; 496():144-155. PubMed ID: 33039559
[TBL] [Abstract][Full Text] [Related]
19. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
[TBL] [Abstract][Full Text] [Related]
20. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K
Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
